Addiction/dependence:
Indications for: VALIUM
Acute alcohol withdrawal.
Adult Dosage:
Initially 10mg 3–4 times during the first 24hrs, then reduce to 5mg 3–4 times daily as needed.
Children Dosage:
Not established.
VALIUM Contraindications:
Children <6months. Myasthenia gravis. Severe respiratory insufficiency. Severe hepatic insufficiency. Sleep apnea syndrome. Acute narrow-angle glaucoma. Untreated open angle glaucoma.
Boxed Warning:
Risks from concomitant use with opioids. Abuse, misuse, and addiction. Dependence and withdrawal reactions.
VALIUM Warnings/Precautions:
Increased risk of drug-related mortality from concomitant use with opioids. Monitor for CNS depressant effects. Discontinue if paradoxical reaction occurs. Respiratory insufficiency. Depression. Suicidal tendencies. Psychosis. May increase severity of seizures. Renal or hepatic impairment. Assess patient's risk for abuse, misuse, addiction prior to and during therapy. Avoid abrupt cessation. Reevaluate periodically. Monitor blood counts, liver function. Inj: not for use in shock, coma, acute alcohol intoxication, or obstetrical conditions. Drug or alcohol abusers. Elderly. Debilitated. Labor & delivery. Neonatal sedation and withdrawal syndrome; monitor neonates exposed during pregnancy or labor. Pregnancy (esp. late stage). Nursing mothers: not recommended.
VALIUM Classification:
Benzodiazepine.
VALIUM Interactions:
Increased sedation, respiratory depression, coma, and death with concomitant opioids; reserve use in those for whom alternative treatment options are inadequate; if needed, limit dosages/durations to minimum and monitor. Potentiates CNS depression with alcohol, other CNS depressants (eg, phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, antihistamines, barbiturates, MAOIs, other antidepressants). Potentiated by CYP3A or CYP2C19 inhibitors (eg, cimetidine, fluoxetine, fluvoxamine, ketoconazole, omeprazole). May affect or be affected by phenytoin.
Adverse Reactions:
Drowsiness, fatigue, muscle weakness, ataxia, CNS effects, GI disturbances, hypotension, salivation changes, neutropenia, jaundice; paradoxical excitement. Inj: apnea, cardiac arrest, venous thrombosis, phlebitis, local irritation, swelling, tonic status epilepticus (when treating petit mal), propylene glycol toxicity, withdrawal reactions.
Drug Elimination:
Renal. Terminal half-life: up to 100 hours (N-desmethyldiazepam).
How Supplied:
Tabs 2mg—100; Tabs 5mg, 10mg—100, 500; Vials (10mL)—contact supplier
Anxiety/OCD:
Indications for: VALIUM
Anxiety.
Adult Dosage:
2–10mg 2–4 times daily. Elderly, debilitated: initially 2–2.5mg 1–2 times daily; increase gradually.
Children Dosage:
<6months: See Contraindications. ≥6months: initially 1–2.5mg 3–4 times daily; increase gradually.
VALIUM Contraindications:
Children <6months. Myasthenia gravis. Severe respiratory insufficiency. Severe hepatic insufficiency. Sleep apnea syndrome. Acute narrow-angle glaucoma. Untreated open angle glaucoma.
Boxed Warning:
Risks from concomitant use with opioids. Abuse, misuse, and addiction. Dependence and withdrawal reactions.
VALIUM Warnings/Precautions:
Increased risk of drug-related mortality from concomitant use with opioids. Monitor for CNS depressant effects. Discontinue if paradoxical reaction occurs. Respiratory insufficiency. Depression. Suicidal tendencies. Psychosis. May increase severity of seizures. Renal or hepatic impairment. Assess patient's risk for abuse, misuse, addiction prior to and during therapy. Avoid abrupt cessation. Reevaluate periodically. Monitor blood counts, liver function. Inj: not for use in shock, coma, acute alcohol intoxication, or obstetrical conditions. Drug or alcohol abusers. Elderly. Debilitated. Labor & delivery. Neonatal sedation and withdrawal syndrome; monitor neonates exposed during pregnancy or labor. Pregnancy (esp. late stage). Nursing mothers: not recommended.
See Also:
VALIUM Classification:
Benzodiazepine.
VALIUM Interactions:
Increased sedation, respiratory depression, coma, and death with concomitant opioids; reserve use in those for whom alternative treatment options are inadequate; if needed, limit dosages/durations to minimum and monitor. Potentiates CNS depression with alcohol, other CNS depressants (eg, phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, antihistamines, barbiturates, MAOIs, other antidepressants). Potentiated by CYP3A or CYP2C19 inhibitors (eg, cimetidine, fluoxetine, fluvoxamine, ketoconazole, omeprazole). May affect or be affected by phenytoin.
Adverse Reactions:
Drowsiness, fatigue, muscle weakness, ataxia, CNS effects, GI disturbances, hypotension, salivation changes, neutropenia, jaundice; paradoxical excitement. Inj: apnea, cardiac arrest, venous thrombosis, phlebitis, local irritation, swelling, tonic status epilepticus (when treating petit mal), propylene glycol toxicity, withdrawal reactions.
Drug Elimination:
Renal. Terminal half-life: up to 100 hours (N-desmethyldiazepam).
How Supplied:
Tabs 2mg—100; Tabs 5mg, 10mg—100, 500; Vials (10mL)—contact supplier
Muscle spasms:
Indications for: VALIUM
Skeletal muscle spasm.
Adult Dosage:
2–10mg 3–4 times daily. Elderly, debilitated: initially 2–2.5mg 1–2 times daily; increase gradually.
Children Dosage:
<6months: See Contraindications. ≥6months: initially 1–2.5mg 3–4 times daily; increase gradually.
VALIUM Contraindications:
Children <6months. Myasthenia gravis. Severe respiratory insufficiency. Severe hepatic insufficiency. Sleep apnea syndrome. Acute narrow-angle glaucoma. Untreated open angle glaucoma.
Boxed Warning:
Risks from concomitant use with opioids. Abuse, misuse, and addiction. Dependence and withdrawal reactions.
VALIUM Warnings/Precautions:
Increased risk of drug-related mortality from concomitant use with opioids. Monitor for CNS depressant effects. Discontinue if paradoxical reaction occurs. Respiratory insufficiency. Depression. Suicidal tendencies. Psychosis. May increase severity of seizures. Renal or hepatic impairment. Assess patient's risk for abuse, misuse, addiction prior to and during therapy. Avoid abrupt cessation. Reevaluate periodically. Monitor blood counts, liver function. Inj: not for use in shock, coma, acute alcohol intoxication, or obstetrical conditions. Drug or alcohol abusers. Elderly. Debilitated. Labor & delivery. Neonatal sedation and withdrawal syndrome; monitor neonates exposed during pregnancy or labor. Pregnancy (esp. late stage). Nursing mothers: not recommended.
See Also:
VALIUM Classification:
Benzodiazepine.
VALIUM Interactions:
Increased sedation, respiratory depression, coma, and death with concomitant opioids; reserve use in those for whom alternative treatment options are inadequate; if needed, limit dosages/durations to minimum and monitor. Potentiates CNS depression with alcohol, other CNS depressants (eg, phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, antihistamines, barbiturates, MAOIs, other antidepressants). Potentiated by CYP3A or CYP2C19 inhibitors (eg, cimetidine, fluoxetine, fluvoxamine, ketoconazole, omeprazole). May affect or be affected by phenytoin.
Adverse Reactions:
Drowsiness, fatigue, muscle weakness, ataxia, CNS effects, GI disturbances, hypotension, salivation changes, neutropenia, jaundice; paradoxical excitement. Inj: apnea, cardiac arrest, venous thrombosis, phlebitis, local irritation, swelling, tonic status epilepticus (when treating petit mal), propylene glycol toxicity, withdrawal reactions.
Drug Elimination:
Renal. Terminal half-life: up to 100 hours (N-desmethyldiazepam).
How Supplied:
Tabs 2mg—100; Tabs 5mg, 10mg—100, 500; Vials (10mL)—contact supplier
Seizure disorders:
Indications for: VALIUM
Adjunct in convulsive disorders.
Adult Dosage:
2–10mg 2–4 times daily. Elderly, debilitated: initially 2–2.5mg 1–2 times daily; increase gradually.
Children Dosage:
<6months: See Contraindications. ≥6months: initially 1–2.5mg 3–4 times daily; increase gradually.
VALIUM Contraindications:
Children <6months. Myasthenia gravis. Severe respiratory insufficiency. Severe hepatic insufficiency. Sleep apnea syndrome. Acute narrow-angle glaucoma. Untreated open angle glaucoma.
Boxed Warning:
Risks from concomitant use with opioids. Abuse, misuse, and addiction. Dependence and withdrawal reactions.
VALIUM Warnings/Precautions:
Increased risk of drug-related mortality from concomitant use with opioids. Monitor for CNS depressant effects. Discontinue if paradoxical reaction occurs. Respiratory insufficiency. Depression. Suicidal tendencies. Psychosis. May increase severity of seizures. Renal or hepatic impairment. Assess patient's risk for abuse, misuse, addiction prior to and during therapy. Avoid abrupt cessation. Reevaluate periodically. Monitor blood counts, liver function. Inj: not for use in shock, coma, acute alcohol intoxication, or obstetrical conditions. Drug or alcohol abusers. Elderly. Debilitated. Labor & delivery. Neonatal sedation and withdrawal syndrome; monitor neonates exposed during pregnancy or labor. Pregnancy (esp. late stage). Nursing mothers: not recommended.
See Also:
VALIUM Classification:
Benzodiazepine.
VALIUM Interactions:
Increased sedation, respiratory depression, coma, and death with concomitant opioids; reserve use in those for whom alternative treatment options are inadequate; if needed, limit dosages/durations to minimum and monitor. Potentiates CNS depression with alcohol, other CNS depressants (eg, phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, antihistamines, barbiturates, MAOIs, other antidepressants). Potentiated by CYP3A or CYP2C19 inhibitors (eg, cimetidine, fluoxetine, fluvoxamine, ketoconazole, omeprazole). May affect or be affected by phenytoin.
Adverse Reactions:
Drowsiness, fatigue, muscle weakness, ataxia, CNS effects, GI disturbances, hypotension, salivation changes, neutropenia, jaundice; paradoxical excitement. Inj: apnea, cardiac arrest, venous thrombosis, phlebitis, local irritation, swelling, tonic status epilepticus (when treating petit mal), propylene glycol toxicity, withdrawal reactions.
Drug Elimination:
Renal. Terminal half-life: up to 100 hours (N-desmethyldiazepam).
How Supplied:
Tabs 2mg—100; Tabs 5mg, 10mg—100, 500; Vials (10mL)—contact supplier
